Skip to main content
Top
Published in: International Urology and Nephrology 1/2024

17-05-2023 | Urokinase | Nephrology - Original Paper

Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients

Authors: Jichao Guan, Shuwen Gong, Qiuli He, Xiaoling Wang, Shuijuan Shen, Xiujuan Wu, Juanping Shan, Tujian Gong, Yanru Yang, Haiying Xie

Published in: International Urology and Nephrology | Issue 1/2024

Login to get access

Abstract

Background

Cardiovascular disease (CVD) is an important cause of morbidity and mortality in peritoneal dialysis (PD) patients. Cardiovascular calcification (CVC) is highly prevalent in PD patients and could predict their cardiovascular mortality. Soluble urokinase plasminogen activator receptor (suPAR) is closely associated with coronary artery calcification in hemodialysis patients and is an important predictor of CVD. However, the role of suPAR in PD patients is poorly understood. We investigated the relationship between serum suPAR and CVC in PD patients.

Methods

Abdominal aortic calcification (AAC) was assessed by lateral lumbar radiography, coronary artery calcification (CAC) by multi-slice computed tomography, and cardiac valvular calcification (ValvC) by echocardiography. CVC was defined as confirmed presence of calcification in one site (AAC, CAC, or ValvC). Patients were divided into CVC group and non-CVC group. Demographic characteristics, biochemical variables, comorbidities, PD regimen, serum suPAR, and medication were compared between the two groups. Logistic regression was conducted to determine association between serum suPAR and presence of CVC. The receiver–operator curve (ROC) was plotted to calculate the area under the curve (AUC) for suPAR to identify CVC and ValvC.

Results

Of 226 PD patients, 111 (49.1%) had AAC, 155 (68.6%) had CAC, and 26 (11.5%) had ValvC. There were significant differences in age, BMI, diabetes, white blood cell, phosphorus, hs-CRP, suPAR, time on dialysis, total volume of dialysate, ultrafiltration, volume of urine, and Kt/V between CVC and non-CVC group. Serum suPAR was associated with CVC by multivariate logistic regression analysis in PD patients, especially in elderly patients. The levels of serum suPAR were closely related to the degree of AAC, CAC, and ValvC in PD patients. The incidence of CVC was higher in patients with higher levels of suPAR. The ROC curve showed that serum suPAR had a predictive value for CVC (AUC = 0.651), especially for ValvC (AUC = 0.828).

Conclusion

Cardiovascular calcification is prevalent in PD patients. High levels of serum suPAR are associated with cardiovascular calcification in PD patients, especially in elderly patients.
Literature
1.
2.
go back to reference Li J, Li Y, Zou Y et al (2022) Use of the systemic inflammation response index (SIRI) as a novel prognostic marker for patients on peritoneal dialysis. Ren Fail 44:1227–1235CrossRefPubMedPubMedCentral Li J, Li Y, Zou Y et al (2022) Use of the systemic inflammation response index (SIRI) as a novel prognostic marker for patients on peritoneal dialysis. Ren Fail 44:1227–1235CrossRefPubMedPubMedCentral
3.
go back to reference KDIGO (2017) Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2011(7):1–59 KDIGO (2017) Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2011(7):1–59
4.
go back to reference Liu ZH, Yu XQ, Yang JW et al (2018) Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin 34:1491–1500CrossRefPubMed Liu ZH, Yu XQ, Yang JW et al (2018) Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin 34:1491–1500CrossRefPubMed
5.
go back to reference Seyahi N, Alagoz S, Atli Z et al (2022) Coronary artery calcification progression and long-term cardiovascular outcomes in renal transplant recipients: an analysis by the joint model. Clin Kidney J 15:101–108CrossRefPubMed Seyahi N, Alagoz S, Atli Z et al (2022) Coronary artery calcification progression and long-term cardiovascular outcomes in renal transplant recipients: an analysis by the joint model. Clin Kidney J 15:101–108CrossRefPubMed
6.
go back to reference Eapen DJ, Manocha P, Ghasemzadeh N et al (2014) Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 3:e1118CrossRef Eapen DJ, Manocha P, Ghasemzadeh N et al (2014) Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 3:e1118CrossRef
7.
go back to reference Drechsler C, Hayek SS, Wei C et al (2017) Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis. Clinical J Am Soc Nephrol 12:1265–1273CrossRef Drechsler C, Hayek SS, Wei C et al (2017) Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis. Clinical J Am Soc Nephrol 12:1265–1273CrossRef
8.
go back to reference Wu W, Cui Y, Hu J et al (2018) Soluble urokinase plasminogen activator receptor is associated with coronary artery calcification and cardiovascular disease in patients undergoing hemodialysis. Kidney Blood Press Res 43:664–672CrossRefPubMed Wu W, Cui Y, Hu J et al (2018) Soluble urokinase plasminogen activator receptor is associated with coronary artery calcification and cardiovascular disease in patients undergoing hemodialysis. Kidney Blood Press Res 43:664–672CrossRefPubMed
10.
go back to reference Kauppila LI, Polak JF, Cupples LA et al (1997) New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132:245–250CrossRefPubMed Kauppila LI, Polak JF, Cupples LA et al (1997) New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132:245–250CrossRefPubMed
11.
go back to reference Agatston AS, Janowitz WR, Hildner FJ et al (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed Agatston AS, Janowitz WR, Hildner FJ et al (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed
12.
go back to reference Wlazel RN, Szwabe K, Guligowska A, et al (2020) Soluble urokinase plasminogen activator receptor level in individuals of advanced age. Sci Rep 10 Wlazel RN, Szwabe K, Guligowska A, et al (2020) Soluble urokinase plasminogen activator receptor level in individuals of advanced age. Sci Rep 10
13.
go back to reference Guan J, Xie H, Wang H et al (2023) Cardiac valve calcification as a predictor of cardiovascular outcomes in peritoneal dialysis patients: an inverse probability of treatment weighting analysis. Int Urol Nephrol 55:1271–1278CrossRefPubMed Guan J, Xie H, Wang H et al (2023) Cardiac valve calcification as a predictor of cardiovascular outcomes in peritoneal dialysis patients: an inverse probability of treatment weighting analysis. Int Urol Nephrol 55:1271–1278CrossRefPubMed
14.
go back to reference Hindy G, Tyrrell DJ, Vasbinder A, et al (2022) Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J Clin Invest 132 Hindy G, Tyrrell DJ, Vasbinder A, et al (2022) Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J Clin Invest 132
15.
go back to reference Nikorowitsch J, Borchardt T, Appelbaum S et al (2020) Cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function. J Am Heart Assoc 9:e15452CrossRef Nikorowitsch J, Borchardt T, Appelbaum S et al (2020) Cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function. J Am Heart Assoc 9:e15452CrossRef
16.
go back to reference Jhee JH, Nam BY, Lee CJ et al (2021) Soluble urokinase-type plasminogen activator receptor, changes of 24-hour blood pressure, and progression of chronic kidney disease. J Am Heart Assoc 10:e17225CrossRef Jhee JH, Nam BY, Lee CJ et al (2021) Soluble urokinase-type plasminogen activator receptor, changes of 24-hour blood pressure, and progression of chronic kidney disease. J Am Heart Assoc 10:e17225CrossRef
17.
go back to reference Shuai T, Yan P, Xiong H et al (2019) Association between soluble urokinase-type plasminogen activator receptor levels and chronic kidney disease: a systematic review and meta-analysis. Biomed Res Int 2019:6927456CrossRefPubMedPubMedCentral Shuai T, Yan P, Xiong H et al (2019) Association between soluble urokinase-type plasminogen activator receptor levels and chronic kidney disease: a systematic review and meta-analysis. Biomed Res Int 2019:6927456CrossRefPubMedPubMedCentral
18.
go back to reference Pawlak K, Pawlak D, Mysliwiec M (2007) Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 119:475–480CrossRefPubMed Pawlak K, Pawlak D, Mysliwiec M (2007) Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 119:475–480CrossRefPubMed
19.
go back to reference Wlazeł RN, Szadkowska I, Bartnicki P et al (2018) Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients. Int Urol Nephrol 50:339–345CrossRefPubMedPubMedCentral Wlazeł RN, Szadkowska I, Bartnicki P et al (2018) Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients. Int Urol Nephrol 50:339–345CrossRefPubMedPubMedCentral
20.
go back to reference Torino C, Pizzini P, Cutrupi S et al (2018) Soluble urokinase plasminogen activator receptor (suPAR) and all-cause and cardiovascular mortality in diverse hemodialysis patients. Kidney Int Rep 3:1100–1109CrossRefPubMedPubMedCentral Torino C, Pizzini P, Cutrupi S et al (2018) Soluble urokinase plasminogen activator receptor (suPAR) and all-cause and cardiovascular mortality in diverse hemodialysis patients. Kidney Int Rep 3:1100–1109CrossRefPubMedPubMedCentral
21.
go back to reference Pawlak K, Mysliwiec M, Pawlak D (2010) Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res 125:e40–e45CrossRefPubMed Pawlak K, Mysliwiec M, Pawlak D (2010) Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res 125:e40–e45CrossRefPubMed
22.
go back to reference Sun M, Chang Q, Xin M et al (2017) Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro. Int J Immunopathol Pharmacol 30:227–237CrossRefPubMedPubMedCentral Sun M, Chang Q, Xin M et al (2017) Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro. Int J Immunopathol Pharmacol 30:227–237CrossRefPubMedPubMedCentral
23.
go back to reference Benz K, Varga I, Neureiter D et al (2017) Vascular inflammation and media calcification are already present in early stages of chronic kidney disease. Cardiovasc Pathol 27:57–67CrossRefPubMed Benz K, Varga I, Neureiter D et al (2017) Vascular inflammation and media calcification are already present in early stages of chronic kidney disease. Cardiovasc Pathol 27:57–67CrossRefPubMed
24.
go back to reference Lyngbaek S, Sehestedt T, Marott JL et al (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781–785CrossRefPubMed Lyngbaek S, Sehestedt T, Marott JL et al (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781–785CrossRefPubMed
25.
go back to reference Sorensen MH, Gerke O, Eugen-Olsen J et al (2014) Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 237:60–66CrossRefPubMed Sorensen MH, Gerke O, Eugen-Olsen J et al (2014) Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 237:60–66CrossRefPubMed
26.
go back to reference Pawlak K, Mysliwiec M, Pawlak D (2008) The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res 122:328–335CrossRefPubMed Pawlak K, Mysliwiec M, Pawlak D (2008) The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res 122:328–335CrossRefPubMed
27.
go back to reference Sánchez Duffhues G, García De Vinuesa A, van de Pol V et al (2019) Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. J Pathol 247:333–346CrossRefPubMedPubMedCentral Sánchez Duffhues G, García De Vinuesa A, van de Pol V et al (2019) Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. J Pathol 247:333–346CrossRefPubMedPubMedCentral
Metadata
Title
Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients
Authors
Jichao Guan
Shuwen Gong
Qiuli He
Xiaoling Wang
Shuijuan Shen
Xiujuan Wu
Juanping Shan
Tujian Gong
Yanru Yang
Haiying Xie
Publication date
17-05-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03623-z

Other articles of this Issue 1/2024

International Urology and Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine